UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.50 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 13.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 80,196 shares of the specialty pharmaceutical company’s stock after selling 12,343 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.15% of Supernus Pharmaceuticals worth $2,501,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $47,000. Innealta Capital LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares in the last quarter. Finally, nVerses Capital LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $72,000.

Supernus Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ:SUPN opened at $36.17 on Friday. The stock has a market cap of $2.00 billion, a P/E ratio of 33.80 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37. The company has a 50 day moving average of $35.30 and a 200 day moving average of $31.94.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.29) earnings per share. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SUPN. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.